Article
In 1950, three scientists were awarded the Nobel Prize for their groundbreaking discovery of steroids, heralded at the time as a "miracle cure" for rheumatoid arthritis (RA).
All News
Article
Recent advancements in targeted therapies, including selective inhibitors of key inflammatory pathways, offer promising outcomes for patients with active psoriatic arthritis (PsA). At ACR 2024, there have been further developments in novel therapies in PsA.
Article
Randomized controlled trials (RCTs) drive guidelines; guidelines drive clinical practice. Because updated guidelines lag trials by many years and dissemination of guidelines takes additional time, rheumatologists often practice “behind the data.” The 2024 ACR Guidelines for the Management of SLE Nephritis reaffirmed many of our typical practice patterns, including hydroxychloroquine for all, renin/angiotensin blockade, and favoring mycophenolate mofetil over cyclophosphamide.
Article
For many women, the journey to motherhood brings a sense of anticipation and joy. However, for those with rheumatoid arthritis, this journey presents unique challenges. At ACR Convergence 2024, researchers discussed how advancements in reproductive medicine and RA management are paving the way for improved outcomes.
Dr. John Cush
Tweet
Where there’s smoke, there’s flare: how pollution fuels RA
The WHO has declared climate change to be the greatest threat to human health in the 21st century, likely to contribute to an additional 250,000 deaths annually between 2030 and 2050 #ACR24
https://t.co/efVzSHXN91 https://t.co/AxRyGpqQFa
Dr. John Cush
Tweet
Sex related differences in PsA
Different factors are known to influence disease characteristics and outcomes in psoriatic arthritis (PsA). Recently, there is new evidence that sex-related differences play a role not only in disease manifestations but also in efficacy and safety… https://t.co/9z9lorLtp0 https://t.co/XZRvm0S585
Dr. John Cush
Tweet
Playing it Safe with RA? JAK vs. TNF Debate
The ORAL surveillance trial raised safety concerns that the janus kinase inhibitor (JAKi) tofacitinib was associated with an increased incidence of cancer and major adverse cardiovascular events (MACE), compared to tumor necrosis… https://t.co/sUSdRKRxEF https://t.co/XcjOqGlLVX
Dr. John Cush
Tweet
SELECT-GCA: Efficacy and Safety of Upadacitinib
Dr. Richard Conway discusses abstract 0770, presented at #ACR24
https://t.co/C9HZIMP9JK https://t.co/zVhFAfLBQe
Dr. John Cush
Tweet
NEW ONLINE POSTER: Safety of a JAKi presented at EULAR 2024!
View safety across 15,000 patient-years of data from 11 Phase 3 trials, including adult patients with RA, PsA, AS, and nr-axSpA. This poster is sponsored by AbbVie US Medical Affairs.
https://t.co/gIFWRqOGmD https://t.co/L0YttKihdf
Dr. John Cush
Tweet
JAK inhibitors in GCA?
We have a phase 3 trial in giant cell arteritis back on the opening day plenary stage. The SELECT-GCA study, looking at upadacitinib in GCA, was scheduled to anchor the #ACR24 opening plenary for a reason - it is highly notable and badly needed.… https://t.co/aJ3uao1wD7 https://t.co/6ao2OoODHg
Dr. John Cush
Tweet
ANCA Vasculitis "Eye": Can rituximab help?
Dr. Janet Pope discusses abstract 0726 at #ACR24
https://t.co/KzYcmjon8D https://t.co/KDIi1vJE4P
Dr. John Cush
Tweet
ORAL Surveillance - Is Statin Use the Problem/Solution?
The findings from ORAL Surveillance Study have been a dominant conversation at #ACR24, with the seminal findings and subsequent analyses a target of debate.
https://t.co/Nn9KSL4dlv https://t.co/gHPwK35eEd
Dr. John Cush
Tweet
Say Goodbye to Methotrexate in PMR?
Despite mixed results on its clinical efficacy in three previous randomised controlled trials (RCTs)1-3, methotrexate is considered the most widely used GC sparing agent. #ACR24
https://t.co/Q5Sw9dvYqJ https://t.co/jvEmg6aPcq
Jiha Lee
Tweet
Time the💉
Response to pneumococcal vaccine better when given before starting MTX.
Stay updated on ACR and EULAR vaccination recommendations!
#ACR24 @RheumNow ABST#2676
Janet Pope
Tweet
#Ianalumab
300 mg sc q monthly
B cell depleted and changes BAFF signalling
👇⬇️IFN
May be promising in #lupus #SLE
+data in primary #Sjogrens
ACR24 @RheumNow @ACRheum
Abst#2425
Needs Phase3
➡️I suspect safer than CAR T and Bispecific T cell engagers but
? ⬇️efficacy
sheila
Tweet
Prof Petri reports the ff predictors of fracture in SLE:
-older age
-Caucasian race
-female sex
⚠️ Prednisone (but not recent IM triamcinolone or IV methylpred) is a MAJOR risk factor.
When possible, avoid prednisone!
@RheumNow #ACR24 #ACRbest abs2679
@rheumarhyme https://t.co/q2NMRaYsAF
Richard Conway
Tweet
Lacaille et al. Long term harms of previous steroids in RA. CV/infection mortality increase 7% every year/use. Takes 3.5 and 10 years to return to normal after 1 and 2 years use. Never returns to normal if >2 years use @RheumNow #ACR24 Abstr#2673 #ACRbest https://t.co/qcp5mCHmeB https://t.co/keXw5Qg2ld
Mike Putman
Tweet
All-caps abstract text throw-down by Michelle Petri re:fractures in SLE 😆
I keep saying this; our obsesssion with vitamin d is not commensurate w/reality
It's. The. Prednisone.
#ACR24 @RheumNow Abstr#2679 #ACRBest https://t.co/13luByNvYT
Mrinalini Dey
Tweet
Does CVD mortality risk change after stopping GC in RA?
➡️28078 incident GC users
➡️Incr mortality risk from CVD &infections persists post-cessation
➡️Risk never returns to pre-GC level after prolonged use
⏩Use GC at lowest dose for shortest time possible
Ab2673 #ACR24 @Rheumnow https://t.co/dtLU8obLke
Jiha Lee
Tweet
Increased risk of mortality related to negative effects of GC use persists long after stopping and never return to pre-GC levels. #GCStewardship
#ACR24 @RheumNow ABST#2673 https://t.co/5AwHDmvQGf
